Fibrosis and diseases of the eye

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 576-586

  Friedlander, Martin ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; FIBROBLAST GROWTH FACTOR; INTEGRIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANGIOGENESIS; BLEEDING; CELL MATURATION; CELL THERAPY; EYE DISEASE; FIBROSIS; GLIOSIS; HUMAN; ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; REVIEW; STEM CELL; VISUAL IMPAIRMENT; WOUND HEALING;

EYE; EYE DISEASES; FIBROSIS; GLIOSIS; HUMANS; MICROGLIA; NEOVASCULARIZATION, PATHOLOGIC; RETINA;

EID: 33847404037     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31030     Document Type: Review

References (122)

1. Dorrell, M.I., Aguilar, E., and Friedlander, M. 2002. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest. Ophthalmol. Vis. Sci. 43:3500-3510.
2. Dorrell, M.I., and Friedlander, M. 2006. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog. Retin. Eye Res. 25:277-295.
3. Gilbert, C.D., and Wiesel, T.N. 1985. Intrinsic connectivity and receptive field properties in visual cortex. Vision Res. 25:365-374.
4. Ferrer, E. 2006. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 19:151-158.
5. Fautsch, M.P., and Johnson, D.H. 2006. Aqueous humor outflow: what do we know? Where will it lead us? Invest. Ophthalmol. Vis. Sci. 47:4181-4187.
6. Ambati, B.K., et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 443:993-997.
7. Cotsarelis, G., Cheng, S.Z., Dong, G., Sun, T.T., and Lavker, R.M. 1989. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. Cell. 57:201-209.
8. Tsubota, K., et al. 1999. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. N. Engl. J. Med. 340:1697-1703.
9. Di Girolamo, N., Chui, J., Coroneo, M.T., and Wakefield, D. 2004. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog. Retin. Eye Res. 23:195-228.
10. Fini, M.E. 1999. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog. Retin. Eye Res. 18:529-551.
11. Lavker, R.M., Tseng, S.C., and Sun, T.T. 2004. Corneal epithelial stem cells at the limbus: looking at some old problems from a new angle. Exp. Eye Res. 78:433-446.
12. Bishop, P.N. 2000. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog. Retin. Eye Res. 19:323-344.
13. Fruttiger, M. 2002. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest. Ophthalmol. Vis. Sci. 43:522-527.
14. Fruttiger, M., et al. 1996. PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron. 17:1117-1131.
15. Bringmann, A., et al. 2006. Muller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 25:397-424.
16. Bok, D. 1993. The retinal pigment epithelium: a versatile partner in vision. J. Cell Sci. Suppl. 17:189-195.
17. Crabb, J.W., et al. 2002. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 99:14682-14687.
18. Rakoczy, P.E., Yu, M.J., Nusinowitz, S., Chang, B., and Heckenlively, J.R. 2006. Mouse models of age-related macular degeneration. Exp. Eye Res. 82:741-752.
19. Michels, S., Schmidt-Erfurth, U., and Rosenfeld, P.J. 2006. Promising new treatments for neovascular age-related macular degeneration. Expert Opin. Investig. Drugs. 15:779-793.
20. Dorrell, M.I., Uusitalo-Jarvinen, H., Aguilar, E., and Friedlander, M. 2007. Ocular neovascularization; basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52(Suppl. 1):S3-S19.
21. Wong, T.Y., et al. 2006. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am. J. Ophthalmol. 141:446-455.
22. Harding, S. 2006. Diabetic retinopathy. Clin. Evid. 15:900-907.
23. Cogan, D.G. 1971. Congenital anomalies of the retina. Birth Defects Orig. Artic. Ser. 7:41-51.
24. Penn, J.S., Tolman, B.L., and Lowery, L.A. 1993. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest. Ophthalmol. Vis. Sci. 34:576-585.
25. Iandiev, I., et al. 2006. Glial cell reactivity in a porcine model of retinal detachment. Invest. Ophthalmol. Vis. Sci. 47:2161-2171.
26. Smith, L.E., et al. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
27. Shing, Y., et al. 1984. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 223:1296-1299.
28. Folkman, J. 1992. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:65-71.
29. Ferrara, N., Houck, K., Jakeman, L., and Leung, D.W. 1992. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13:18-32.
30. Fett, J.W., et al. 1985. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 24:5480-5486.
31. Antonelli-Orlidge, A., Saunders, K.B., Smith, S.R., and D'Amore, P.A. 1989. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. U. S. A. 86:4544-4548.
32. Brem, R.B., et al. 1994. Immunolocalization of integrins in the human retina. Invest. Ophthalmol. Vis. Sci. 35:3466-3474.
33. Beutler, B., and Cerami, A. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 320:584-588.
34. Ishikawa, F., et al. 1989. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 338:557-562.
35. Ezekowitz, R.A., Mulliken, J.B., and Folkman, J. 1992. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456-1463.
36. D'Amato, R.J., Loughnan, M.S., Flynn, E., and Folkman, J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:4082-4085.
37. Tolsma, S.S., et al. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122:497-511.
38. Derynck, R. 1990. Transforming growth factor-alpha. Mol. Reprod. Dev. 27:3-9.
39. O'Reilly, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.
40. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M., and Cheresh, D.A. 1998. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:391-400.
41. Wakasugi, K., et al. 2002. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:173-177.
42. Otani, A., et al. 2002. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:178-183.
43. Dawson, D.W., et al. 1999. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 285:245-248.
44. D'Amore, P.A. 1994. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 35:3974-3979.
45. Leavesley, D.I., Schwartz, M.A., Rosenfeld, M., and Cheresh, D.A. 1993. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol. 121:163-170.
46. Brooks, P.C., Clark, R.A., and Cheresh, D.A. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569-571.
47. Friedlander, M., et al. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1500-1502.
48. Kim, S., Harris, M., and Varner, J.A. 2000. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J. Biol. Chem. 275:33920-33928.
49. Friedlander, M., et al. 1996. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U. S. A. 93:9764-9769.
50. Elner, S.G., and Elner, V.M. 1996. The integrin superfamily and the eye. Invest. Ophthalmol. Vis. Sci. 37:696-701.
51. Fini, M.E., and Girard, M.T. 1990. Expression of collagenolytic/ gelatinolytic metalloproteinases by normal cornea. Invest. Ophthalmol. Vis. Sci. 31:1779-1788.
52. Brown, D., Hamdi, H., Bahri, S., and Kenney, M.C. 1994. Characterization of an endogenous metalloproteinase in human vitreous. Curr. Eye Res. 13:639-647.
53. Jones, B.E., et al. 1994. Characterization and novel activation of 72-kDa metalloproteinase in retinal interphotoreceptor matrix and Y-79 cell culture medium. Exp. Eye Res. 59:257-269.
54. Alexander, J.P., Bradley, J.M., Gabourel, J.D., and Acott, T.S. 1990. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 31:2520-2528.
55. Arias-Salgado, E.G., et al. 2003. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc. Natl. Acad. Sci. U. S. A. 100:13298-13302.
56. Weick, M., Wiedemann, P., Reichenbach, A., and Bringmann, A. 2005. Resensitization of P2Y receptors by growth factor-mediated activation of the phosphatidylinositol-3 kinase in retinal glial cells. Invest. Ophthalmol. Vis. Sci. 46:1525-1532.
57. Alavi, A., Hood, J.D., Frausto, R., Stupack, D.G., and Cheresh, D.A. 2003. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 301:94-96.
58. Miller, J.W., et al. 1994. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145:574-584.
59. Aiello, L.P. 1997. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 29:354-362.
60. Aiello, L.P., et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487.
61. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-1028.
62. Amano, S., Rohan, R., Kuroki, M., Tolentino, M., and Adamis, A.P. 1998. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 39:18-22.
63. Hanneken, A., et al. 1991. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch. Ophthalmol. 109:1005-1011.
64. Kitaoka, T., Morse, L.S., Schneeberger, S., Ishigooka, H., and Hjelmeland, L.M. 1997. Expression of FGF5 in choroidal neovascular membranes associated with ARMD. Curr. Eye Res. 16:396-399.
65. Rousseau, B., Larrieu-Lahargue, F., Bikfalvi, A., and Javerzat, S. 2003. Involvement of fibroblast growth factors in choroidal angiogenesis and retinal vascularization. Exp. Eye Res. 77:147-156.
66. Mordenti, J., et al. 1999. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol. Pathol. 27:14-21.
67. Drolet, D.W., et al. 2000. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503-1510.
68. Seo, M.S., et al. 1999. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. 154:1743-1753.
69. Hammes, H.P., Brownlee, M., Jonczyk, A., Sutter, A., and Preissner, K.T. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2:529-533.
70. Luna, J., Tobe, T., Mousa, S.A., Reilly, T.M., and Campochiaro, P.A. 1996. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. 75:563-573.
71. Boger, D.L., Goldberg, J., Silletti, S., Kessler, T., and Cheresh, D.A. 2001. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). J. Am. Chem. Soc. 123:1280-1288.
72. Silletti, S., Kessler, T., Goldberg, J., Boger, D.L., and Cheresh, D.A. 2001. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:119-124.
73. Das, A., and McGuire, P.G. 2003. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog. Retin. Eye Res. 22:721-748.
74. Gupta, A.R., et al. 2001. Strain-dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF). J. Gene Med. 3:252-259.
75. Crum, R., Szabo, S., and Folkman, J. 1985. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 230:1375-1378.
76. Clark, A.F., et al. 1999. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest. Ophthalmol. Vis. Sci. 40:2158-2162.
77. Penn, J.S., Rajaratnam, V.S., Collier, R.J., and Clark, A.F. 2001. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 42:283-290.
78. Qi, J.H., et al. 2003. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9:407-415.
79. Grant, M.B., Caballero, S., and Millard, W.J. 1993. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul. Pept. 48:267-278.
80. Danesi, R., et al. 1997. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin. Cancer Res. 3:265-272.
81. Smith, L.E., et al. 1997. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 276:1706-1709.
82. Bressler, N.M., et al. 2005. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch. Ophthalmol. 123:1283-1285.
83. Rosenfeld, P.J., et al. 2006. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431.
84. Dorrell, M.I., Aguilar, E., Scheppke, L., Barnett, F.H., and Friedlander, M. 2007. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 104:967-972.
85. Fischer, A.J., et al. 2004. Different aspects of gliosis in retinal Muller glia can be induced by CNTF, insulin, and FGF2 in the absence of damage. Mol. Vis. 10:973-986.
86. Dyer, M.A., and Cepko, C.L. 2000. Control of Muller glial cell proliferation and activation following retinal injury. Nat. Neurosci. 3:873-880.
87. Honjo, M., et al. 2000. Expression of ciliary neurotrophic factor activated by retinal Muller cells in eyes with NMDA- and kainic acid-induced neuronal death. Invest. Ophthalmol. Vis. Sci. 41:552-560.
88. Strauss, O. 2005. The retinal pigment epithelium in visual function. Physiol. Rev. 85:845-881.
89. Campochiaro, P.A. 1993. Cytokine production by retinal pigmented epithelial cells. Int. Rev. Cytol. 146:75-82.
90. Folkman, J. 2006. Angiogenesis. Annu. Rev. Med. 57:1-18.
91. Korbling, M., and Estrov, Z. 2003. Adult stem cells for tissue repair - a new therapeutic concept? N. Engl. J. Med. 349:570-582.
92. Cahill, M.T., Freedman, S.F., and Toth, C.A. 2003. Macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch. Ophthalmol. 121:132-133.
93. Lai, J.C., et al. 2002. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch. Ophthalmol. 120:1317-1324.
94. Huang, J.C., Ishida, M., Hersh, P., Sugino, I.K., and Zarbin, M.A. 1998. Preparation and transplantation of photoreceptor sheets. Curr. Eye Res. 17:573-585.
95. Ishida, M., Lui, G.M., Yamani, A., Sugino, I.K., and Zarbin, M.A. 1998. Culture of human retinal pigment epithelial cells from peripheral scleral flap biopsies. Curr. Eye Res. 17:392-402.
96. Dandekar, S.S., et al. 2005. Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch. Ophthalmol. 123:1507-1513.
97. Tao, W., et al. 2002. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 43:3292-3298.
98. Bush, R.A., et al. 2004. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest. Ophthalmol. Vis. Sci. 45:2420-2430.
99. Tao, W. 2006. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin. Biol. Ther. 6:717-726.
100. Klimanskaya, I., et al. 2004. Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics. Cloning Stem Cells. 6:217-245.
101. Lund, R.D., et al. 2006. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 8:189-199.
102. Jin, H., et al. 2006. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116:652-662. doi:10.1172/JCI24751.
103. Otani, A., et al. 2002. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat. Med. 8:1004-1010.
104. Otani, A., et al. 2004. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage negative hematopoietic stem cells. J. Clin. Invest. 114:765-774. doi:10.1172/JCI200421686.
105. Krause, D.S. 2002. Plasticity of marrow-derived stem cells. Gene Ther. 9:754-758.
106. Blau, H., Brazelton, T., Keshet, G., and Rossi, F. 2002. Something in the eye of the beholder. Science. 298:361-362.
107. Barber, C.L., and Iruela-Arispe, M.L. 2006. The ever-elusive endothelial progenitor cell: identities, functions and clinical implications. Pediatr. Res. 59:26R-32R.
108. Grant, M.B., et al. 2003. The contribution of adult hematopoietic stem cells to retinal neovascularization. Adv. Exp. Med. Biol. 522:37-45.
109. Espinosa-Heidmann, D.G., Caicedo, A., Hernandez, E.P., Csaky, K.G., and Cousins, S.W. 2003. Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:4914-4919.
110. Sengupta, N., et al. 2003. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:4908-4913.
111. Csaky, K.G., et al. 2004. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp. Eye Res. 78:1107-1116.
112. Dorrell, M.I., Otani, A., Aguilar, E., Moreno, S.K., and Friedlander, M. 2004. Adult bone marrow-derived stem cells utilize R-cadherin to target sites of neovascularization in the developing retina. Blood. 103:3420- 3427.
113. Ritter, M.R., et al. 2006. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J. Clin. Invest. 116:3266-3276. doi:10.1172/JCI29683.
114. Quaini, F., et al. 2002. Chimerism of the transplanted heart. N. Engl. J. Med. 346:5-15.
115. Asahara, T., et al. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964-967.
116. Hill, J.M., et al. 2003. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348:593-600.
117. Werner, N., et al. 2005. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353:999-1007.
118. Kawamoto, A., et al. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 103:634-637.
119. Grunewald, M., et al. 2006. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 124:175-189.
120. Bailey, A.S., et al. 2006. Myeloid lineage progenitors give rise to vascular endothelium. Proc. Natl. Acad. Sci. U. S. A. 103:13156-13161.
121. Nakazawa, T., et al. 2007. Monocyte chemoattractant protein-1 mediates retinal detachment-induced photoreceptor apoptosis. Proc. Natl. Acad. Sci. U. S. A. 104:2425-2430.
122. Sarraf, D. 2001. A slide-script program: diabetes and eye disease [slide]. American Academy of Ophthalmology. San Francisco, California, USA.